加载中
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
前收盘价
US$78.17
+US$0.30 · +0.39%
盘前
US$78.17
US$0.00 · 0.00%
10月13日 4:00 ET
盘中时间采用ET。市场数据可能有所延迟。
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
日内区间
当前US$78.17
52周区间
当前US$78.17
盘中时间采用ET。市场数据可能有所延迟。
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
日内区间
当前US$78.17
52周区间
当前US$78.17
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6.05亿 USD | 4.42亿 USD | 2.42亿 USD | 9345.9万 USD | 3026.2万 USD |
| 销货成本 | 2.43亿 USD | 1.79亿 USD | 8753万 USD | 2818.7万 USD | 910.3万 USD |
| 毛利 | 3.63亿 USD | 2.62亿 USD | 1.54亿 USD | 6527.2万 USD | 2115.9万 USD |
| 研究与开发 | 6905.5万 USD | 5596.8万 USD | 6326.7万 USD | 2681.2万 USD | 2230.4万 USD |
| 销售、一般及管理费用 | 1.85亿 USD | 1.69亿 USD | 1.2亿 USD | 6989.7万 USD | 3828.3万 USD |
| 营业费用 | 2.54亿 USD | 2.25亿 USD | 1.83亿 USD | 9670.9万 USD | 6058.7万 USD |
| 利息收入 | — | — | 1250万 USD | 90万 USD | — |
| 利息支出 | 1378.2万 USD | 1440.9万 USD | 1079.1万 USD | 372.6万 USD | 387.4万 USD |
| 折旧和摊销 | 2718.5万 USD | 1975.8万 USD | 817.7万 USD | 347.8万 USD | 181.7万 USD |
| 营业利润 | 1.09亿 USD | 3749.6万 USD | −2872.7万 USD | −3143.7万 USD | −3942.8万 USD |
| 净利润 | 1.9亿 USD | 3546.4万 USD | −2502.8万 USD | −3623.1万 USD | −4421.5万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$99.75
上涨空间 27.61%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI8839.14万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM6950.33万0.09%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Morningstar Small-Cap ETFVB6406.5万0.03%1853亿 USD0.03%US$288.16-0.46%
Vanguard Morningstar Small-Cap Growth ETFVBK3670.16万0.08%447亿 USD0.05%US$340.88-1.12%
Vanguard Extended Market ETFVXF3410.28万0.04%954亿 USD0.05%US$233.52-0.63%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM2485.4万0.16%157.12亿 USD0.03%US$53.42-0.06%
iShares Russell 2000 Growth ETFIWO2469.02万0.18%139.17亿 USD0.24%US$353.71-0.86%
YieldMax Ultra Option Income Strategy ETFULTY2255.2万3.25%7亿 USD1.40%US$25.32-0.78%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMiShares Russell 2000 Growth ETFIWOYieldMax Ultra Option Income Strategy ETFULTYAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
